Over 6-year survival in locally advanced cholangiocarcinoma – a case report

Cristina Zugun-Eloae, Mihaela Ginghină, Gheorghe Gh. Bălan, Delia Gabriela Ciobanu-Apostol, Raluca Bălan, Dana-Elena Mitrică


Cholangiocarcinoma is a malignancy of the biliary duct system that may originate in the liver and extrahepatic bile duct. Despite aggressive anticancer therapy and interventional supportive care, the overall survival is approximatively 6 months, most patients not being eligible for curative resection. Case description: A 64 year-old patient, diagnosed in 2008 with locally advanced bile duct neoplasm (T3N0M0), who underwent latero-lateral hepatoduodenal anastomosis and cholecystectomy in 2008, followed by neoadjuvant Gemcitabine chemotherapy and cephalic duodenopancreatectomy with tumor exeresis in 2009, uncompliant to follow-up, presents with abdominal meteorism, diffuse abdominal pain, inappetence, weight loss and increased fatigability. Initial ultrasonography showed a localized pancreatic tumor and liquid in the Douglas pouch, both confirmed by CT scan. Discussion: The 6-year survival compared to the general mean survival rate of 17 months, depending on the type of the neoplasm, raises questions about the otherwise histopathology confirmed diagnosis of well differentiated cholangiocarcinoma. The present image documented pancreatic tumor makes the retrospective diagnosis assessment even more intricate. Slow-progressor outlier cases might represent new diagnostic entities, and their understanding can be instrumental in improving the therapeutic efficiency. Long time survival in such diagnostic entities is scarcely reported in literature.


Cholangiocarcinoma, survival rate, pancreatic tumor

Full Text:



Rizvi S, Gores GJ. Current Diagnostic and Management Options in Perihilar Cholangiocarcinoma. Digestion 2014; 89:216-222.

Ghouri YA, Mian I, Blechacz B. Cancer review: Cholangiocarcinoma. J Carcinog 2015; 14:1.

Tyson GL, El-Serag HB. Risk Factors of Cholangiocarcinoma. Hepatology 2011; 54(1):173-184.

Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and Treatment of Cholangiocarcinoma. The Oncologist 2004; 9(1):43-57.

Pattanathien P, Khuntikeo N, Promthet S, Kamsa-Ard S. Survival Rate of Extrahepatic Cholangiocarcinoma Patients after Surgical Treatment in Thailand. Asian Pac J Cancer Prev 2013; 14(1):321-324.

Nakeeb A, Pitt HA. Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HBP (Oxford) 2005; 7(4):278–282.

Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and Cancer, A consensus report. Diabetes Care 2010; 33(7):1674-1685.

Kang X, Kong F, Wu X, et al. High Glucose Promotes Tumor Invasion and Increases Metastasis-Associated Protein Expression in Human Lung Epithelial Cells by Upregulating Heme Oxygenase-1 via Reactive Oxygen Species or the TGF-β1/PI3K/Akt Signaling Pathway. Cell Physiol Biochem 2015; 35:1008-1022.

DOI: http://dx.doi.org/10.22551/2015.06.0202.10035

Copyright (c) 2015 Archive of Clinical Cases

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975